JYNT Earnings Prediction
The chart below shows how JYNT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, JYNT sees a +6.24% change in stock price 10 days leading up to the earnings, and a +3.15% change 10 days following the report. On the earnings day itself, the stock moves by -1.77%. This data can give you a slight idea of what to expect for the next quarter's release.
JYNT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
30.20M
2.46%
-0.21%
Gross Margin
86.55%
4.04%
1.09%
Operating Margin
2.05%
10150.00%
-130.06%
Net Margin
-10.48%
331.28%
-11.78%
EPS
-0.21
-320.00%
-12.50%
No Data Available
JYNT Earnings Analysis
The Joint Corp. Corporation (JYNT.O) Earnings Conference Call
Positive
Revenue Increase Q3 2023: Revenue increased to $90.2 million, up 4% compared to Q3 2023.
Clinic Sales Increase: System-wide sales for all clinics opened for any amount of time increased to $129.3 million, up 8%.
Franchise Revenue Increase: Revenue from franchise operations increased 9%, contributing $12.7 million, reflecting the increased number of clinics in operation.
Franchise Clinics EBITDA Growth: Adjusted EBITDA increased 9% to $5.8 million for franchise clinics, demonstrating strong operational performance.
Franchise Network Expansion: At September 30, 2024, total clinic count reached 963 with 838 franchise clinics, indicating continued growth in the franchise network.
Negative
Net Loss Analysis: Net loss was $5.8 million, including $5.6 million in loss on disposition or impairment and the Q2 $1.5 million litigation expense or a loss of $0.39 per share.
EBITDA Comparison: Adjusted EBITDA was $2.4 million compared to $2.9 million.
Clinic Revenue Decline: Company-owned or managed clinic revenue decreased 2%, contributing $17.5 million, reflecting improved same-store sales growth in newer clinics, partially offset by fewer clinics in operation.
Marketing Expense Increase: Selling and marketing expenses were $4.8 million, up 11% year-over-year, reflecting the timing of the advertising spend.
Impairment Loss Comparison: Loss on disposition or impairment was $3.8 million related to the quarterly analysis of clinics held for sale as part of the refranchising efforts compared to $905,000 in Q3 2023.
JYNT FAQs
How does JYNT typically perform around its earnings report dates?
Is The Joint Corp. (JYNT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
JYNT Earning Call Sentiment
The Joint Corp. (JYNT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
JYNT.O
1.23%Positive
The earnings call reveals several negative indicators: increased net loss, decreased adjusted EBITDA, and a downward revision of guidance due to economic headwinds. Although there are positive aspects like an 8% increase in system-wide sales and strategic refranchising, the financial health and market strategy ratings are low due to widening losses and unclear management responses in the Q&A. The refranchising strategy and potential growth are overshadowed by immediate financial challenges and uncertainties, leading to a likely stock price decline.
